SciSparc Ltd.宣布,其子公司Neurothera Labs已获得附条件的监管批准,得以推进对Cliniquantum的收购事宜。此项批准标志着该交易在满足特定规定条件后,即将进入下一关键阶段。
SciSparc Ltd.宣布,其子公司Neurothera Labs已获得附条件的监管批准,得以推进对Cliniquantum的收购事宜。此项批准标志着该交易在满足特定规定条件后,即将进入下一关键阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.